Welcome to our dedicated page for Galapagos Nv SEC filings (Ticker: GLPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Galapagos NV filings document foreign-issuer disclosures made primarily on Form 6-K, including material events, shareholder meeting results, governance actions, capital-structure updates and clinical or regulatory communications. The records cover annual and extraordinary meeting votes, remuneration and board matters, subscription right plans, registration-statement incorporation, and transparency notifications under Belgian ownership-disclosure rules.
The company’s filings also include press releases and corporate presentations related to strategic collaborations, T cell engager and cell-therapy programs, operating and financial results, and shareholder voting mechanics. For this ADR-listed biotechnology issuer, the filing record ties business development, pipeline disclosures, ownership thresholds, employee equity instruments and corporate-governance approvals to formal U.S. securities reporting.
Galapagos NV has appointed Tania Philipp as Chief Human Resources Officer, effective March 4, 2026. She will also join the Management Committee, reflecting her senior role in shaping the company’s people strategy.
Philipp succeeds Annelies Missotten, who will remain with Galapagos through June 30, 2026 to support a smooth transition. Philipp brings nearly three decades of executive-level HR experience in life sciences, including roles at Vor Bio, Tango Therapeutics and Bavarian Nordic. Galapagos describes itself as a biotechnology company focused on acquiring and advancing medicines in oncology and immunology & inflammation for serious diseases with unmet need.
Galapagos NV reported that Bank of America Corporation and affiliates crossed the 5% major shareholding threshold under Belgian transparency rules through transactions in Galapagos voting rights and equivalent financial instruments. On February 26, 2026 they first moved above 5%, then adjusted their position the following day.
As of March 2, 2026, Bank of America and its affiliates held 292,642 voting rights and 3,491,679 equivalent financial instruments, together representing 5.74% of Galapagos’ 65,897,071 outstanding shares. The notifications detail holdings across several entities, including BofA Securities and Merrill Lynch International, using instruments such as rights to recall, rights of use, options, and swaps.
Galapagos NV reported full-year 2025 results and described a major strategic reset toward a business development-led model. Total net revenues rose to €1,112.2 million, largely driven by releasing €1,069.0 million of deferred income from its collaboration with Gilead, leading to operating profit of €295.1 million and net profit of €320.9 million.
The company is winding down its cell therapy activities, recording an impairment of €228.1 million and additional restructuring costs, and also reorganized its small molecule business. Despite these charges, year-end 2025 cash and financial investments remained high at €2,998.0 million. Management guides to be cash flow neutral to positive by the end of 2026 and expects year-end 2026 cash between €2.775 and €2.850 billion, while shrinking to about 35–40 employees and focusing on transformative deals in oncology and immunology.
Galapagos NV filed a report announcing that Dr. Paulo Fontoura has been appointed by way of co-optation as a Non-Executive Independent Director to its Board of Directors, effective February 9, 2026. He replaces Dr. Susanne Schaffert, who stepped down from the Board on November 1, 2025.
Dr. Fontoura has 20 years of pharmaceutical industry experience across neurology, immunology, ophthalmology, and rare diseases. He currently serves as Chief Medical Officer at Xaira and previously led clinical development in multiple therapeutic areas at Roche, with academic roots in neuroimmunology and ongoing teaching roles in Europe.
Galapagos reported that Bank of America Corporation crossed the 5% disclosure threshold in its shares under Belgian transparency rules. The change followed an acquisition of Galapagos voting rights and equivalent financial instruments on February 9, 2026.
As of February 11, 2026, Bank of America and affiliates held 104,522 direct voting rights and 3,415,894 equivalent financial instruments in Galapagos, representing together 5.34% of the company’s 65,897,071 outstanding shares. The notification formalizes Bank of America’s status as a significant shareholder.
Galapagos NV reports that Bank of America Corporation repeatedly crossed Belgian disclosure thresholds around 5% of its voting rights in early February 2026.
Notifications show Bank of America and affiliates moving from 5.33% to 7.23%, then back down to 5.04% of Galapagos’ voting rights and equivalent financial instruments within four days.
As of February 5, 2026, Bank of America and its affiliates held 132,087 direct voting rights and 3,323,941 equivalent financial instruments, representing together 5.04% of Galapagos’ 65,897,071 currently outstanding shares.
Galapagos NV submitted a Form 6-K as a foreign private issuer, confirming it files annual reports on Form 20-F. The filing states that a press release dated December 18, 2025, attached as Exhibit 99.1, has been furnished. The company also explains that the information in this Form 6-K, including Exhibit 99.1 but excluding specific quotes from Dr. Rohit Aggarwal and Henry Gosebruch, is incorporated by reference into multiple Galapagos employee share-based compensation registration statements on Form S-8.
Galapagos submitted a Form 6-K as a foreign private issuer for November 2025, confirming it files annual reports on Form 20-F. The filing mainly furnishes a press release dated November 3, 2025 as Exhibit 99.1 and incorporates that information into multiple existing employee equity plan registration statements on Form S-8.